Due to this gain of oncogenic AR function, prostate cancers (PCa) initially are nearly universally responsive to androgen deprivation therapy (ADT), since this induces an autocrine TGFβ-stimulated apoptotic death of such malignant ligand/AR (A+/AR+)-dependent PCa cells [7,19]. The gene discussed is TGFB1; the disease is posterior cortical atrophy.